Skip to main content
Premium Trial:

Request an Annual Quote

ViroSeq Gets FDA Clearance for use on ABI s 3700 DNA Analyzer

NEW YORK, June 25 - Celera Diagnostics today said that the US Food and Drug Administration has granted an additional marketing clearance for the company's ViroSeq HIV-1 genotyping system, a molecular diagnostic.


The 510(k) clearance covers the use of the ViroSeq system with the ABI Prism 3700 DNA analyzer, a product sold by Celera of Alameda, Calif., a joint venture between Applied Biosystems Group, Celera Genomics of Applera, and Abbott Laboratories. Abbott distributes the test, which is used to monitor and treat HIV infection.


The FDA cleared the ViroSeq system for marketing in December as an in vitro  diagnostic. ViroSeq uses DNA sequencing technology to identify strains of the HIV-1 virus, targeting regions of the viral genome associated with drug-resistant mutations. Some 150,000 HIV genotyping tests are conducted each year, according to Celera.
The Scan

Follow-Up Data Requests to Biobank Participants Ineffective, Study Finds

An effort to recontact biobank enrollees for additional information reports low participation in a new BMJ Open study.

Study Finds Widespread Transmission of Resistant Bacteria in Vietnam Hospitals

A sequencing study in The Lancet Microbe finds widespread transmission of drug-resistant Escherichia coli, Klebsiella pneumoniae, and Acinetobacter baumannii in two Vietnam ICUs.

Novel Brain Cell Organoids Show Promise for Autism Research

University of Utah researchers report in Nature Communications on their development of brain cell organoids to study SHANK3-related autism.

Study Finds Few FDA Post-Market Regulatory Actions Backed by Research, Public Assessments

A Yale University-led team examines in The BMJ safety signals from the US FDA Adverse Event Reporting System and whether they led to regulatory action.